Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aileen L Pangan

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Clinical Pharmacology and Therapeutics|October 15, 2019
Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid ArthritisAhmed Nader, Mohamed-Eslam F Mohamed, Insa Winzenborg, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 28, 2016
Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back PainAtul Deodhar, Philip J Mease, John D Reveille, et al.
The Journal of Rheumatology|October 5, 2010
Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIERDésirée van der Heijde, Ferdinand C Breedveld, Arthur Kavanaugh, et al.
Arthritis Care & Research|February 22, 2011
Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registryDaniel E Furst, Aileen L Pangan, Leslie R Harrold, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 8, 2011
Is the Health Utilities Index 3 valid for patients with ankylosing spondylitis?Katherine Gooch, David Feeny, Robert L Wong, et al.
Annals of the Rheumatic Diseases|August 7, 2015
A psychometric analysis of outcome measures in peripheral spondyloarthritisMaureen C Turina, Sofia Ramiro, Dominique L Baeten, et al.
Arthritis Research & Therapy|January 7, 2021
Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka, et al.
The New England Journal of Medicine|October 14, 2020
Trial of Upadacitinib or Abatacept in Rheumatoid ArthritisAndrea Rubbert-Roth, Jeffrey Enejosa, Aileen L Pangan, et al.
Arthritis Care & Research|July 31, 2015
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related ArthritisRubén Burgos-Vargas, Shirley M L Tse, Gerd Horneff, et al.
RMD Open|March 14, 2018
Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2Filip Van den Bosch, Philip J Mease, Joachim Sieper, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Clinical Pharmacology and Therapeutics|October 15, 2019
Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid ArthritisAhmed Nader, Mohamed-Eslam F Mohamed, Insa Winzenborg, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 28, 2016
Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back PainAtul Deodhar, Philip J Mease, John D Reveille, et al.
The Journal of Rheumatology|October 5, 2010
Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIERDésirée van der Heijde, Ferdinand C Breedveld, Arthur Kavanaugh, et al.
Arthritis Care & Research|February 22, 2011
Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registryDaniel E Furst, Aileen L Pangan, Leslie R Harrold, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 8, 2011
Is the Health Utilities Index 3 valid for patients with ankylosing spondylitis?Katherine Gooch, David Feeny, Robert L Wong, et al.
Annals of the Rheumatic Diseases|August 7, 2015
A psychometric analysis of outcome measures in peripheral spondyloarthritisMaureen C Turina, Sofia Ramiro, Dominique L Baeten, et al.
Arthritis Research & Therapy|January 7, 2021
Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka, et al.
The New England Journal of Medicine|October 14, 2020
Trial of Upadacitinib or Abatacept in Rheumatoid ArthritisAndrea Rubbert-Roth, Jeffrey Enejosa, Aileen L Pangan, et al.
Arthritis Care & Research|July 31, 2015
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related ArthritisRubén Burgos-Vargas, Shirley M L Tse, Gerd Horneff, et al.
RMD Open|March 14, 2018
Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2Filip Van den Bosch, Philip J Mease, Joachim Sieper, et al.
Pageof 5